Promega, GA1230, T Cell Activation Bioassay (TCRαβ-KO)

Tools to Screen and Characterize Transgenic TCR
Identify TCRs specific for a peptide/HLA of interest
Test specificity of candidate TCR
Specifications：
TCRαβ-KO (CD4+) Cells (CPM) GA117A 2 × 1ml
TCRαβ-KO (CD8+) Cells (CPM) GA116A 2 × 1ml
TCRαβ-KO (CD4+, CD8+) (CPM) GA118A 2 × 1ml
TCRαβ-KO (CD4+) Cells (CPM) GA117A 50 × 1ml
TCRαβ-KO (CD8+) Cells (CPM) GA116A 50 × 1ml
TCRαβ-KO (CD4+, CD8+) (CPM) GA118A 50 × 1ml
Adoptive T cell immunotherapy is an important cancer treatment strategy in which genetically modified T cells are made tumor-specific and activated via introduction of a transgenic antigen receptor, which improves their ability to recognize and destroy tumors. T cell receptor-engineered T cell (TCR-T) and chimeric antigen receptor T cell (CAR-T) therapy are two types of adoptive T cell immunotherapy.
Measurement of TCR activation using traditional methods relies on laborious protocols and highly variable end points. The TCRαβ-KO Bioassay overcomes the limitations of these existing methods and enables functional testing of transgenic TCRs for antigen ranking, specificity and safety testing for applications such as quality control, TCR-T and CAR-T therapies.
The T Cell Activation Bioassay (TCRαβ-KO) is a bioluminescent cell-based assay for measuring the potency of transgenic TCR constructs to activate T cells without the constraints of endogenous TCR expression. The assay consists of a genetically engineered Jurkat T cell line with endogenous TCR α and β chains knocked out using CRISPR/Cas9. These cells express a luciferase reporter driven by a TCR pathway-dependent promoter.
TCRαβ-KO Bioassay is available in CPM and Cell Bank formats:
The TCR Transfection Positive Control Kit is available separately. If interested, please note as part of your inquiry.